Literature DB >> 12189508

Prognostic impact of metallothionein on oral squamous cell carcinoma.

Sérgio V Cardoso1, Hugo M Barbosa, Ignez M Candellori, Adriano M Loyola, Maria Cássia F Aguiar.   

Abstract

Metallothionein (MT), a low-molecular-weight protein with high cysteine content, seems to be related to neoplastic resistance to oncologic treatment and therefore has been studied as a prognostic factor for a variety of human malignant tumors. MT overexpression in neoplasms of ectodermal origin is usually associated with a poor prognosis. MT expression was evaluated in 60 samples of oral squamous cell carcinoma by immunohistochemistry to study its prognostic influence on oral cancer. Possible associations of MT immunoexpression were also investigated with respect to clinical stage (TNM), histological grading, and proliferation index (Ki-67) of the lesions. No significant statistical correlation was observed among these variables. The impact on overall survival was assessed by uni and multivariate statistical tests. Mean MT labeling index was 60%. High MT labeling indexes (over 76%) predicted shorter survival in univariate statistical analysis. In multivariate analysis, MT labeling index and clinical stage were independent prognostic factors. MT overexpression in oral squamous cell carcinoma seems to be related to a worse prognosis for patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189508     DOI: 10.1007/s00428-001-0588-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  8 in total

1.  Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.

Authors:  David J Feith; Anthony E Pegg; Louise Y Y Fong
Journal:  Carcinogenesis       Date:  2012-12-07       Impact factor: 4.944

2.  Immunoexpression of Metallothionein in Oral Squamous Cell Carcinoma.

Authors:  Rakesh Kumar Dumpala; Venkateswara Rao Guttikonda
Journal:  J Maxillofac Oral Surg       Date:  2015-03-18

3.  Metallothionein immunoexpression in non-syndromic and syndromic keratocystic odontogenic tumour.

Authors:  Aline-Cristina-Batista-Rodrigues Johann; Patrícia-Carlos Caldeira; Marcelo-Vidigal Caliari; Ricardo-Santiago Gomez; Maria-Cássia-Ferreira Aguiar; Ricardo-Alves Mesquita
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-07-01

4.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 5.  The roles of metallothioneins in carcinogenesis.

Authors:  Manfei Si; Jinghe Lang
Journal:  J Hematol Oncol       Date:  2018-08-23       Impact factor: 17.388

6.  Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.

Authors:  Lei Wang; Fuli Xin; Nanping Lin; Yingchao Wang; Xiaolong Liu; Jingfeng Liu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Metallothionein Expression and its Influence on the In Vitro Biological Behavior of Mucoepidermoid Carcinoma.

Authors:  João Rafael Habib Souza Aquime; Lara Carolina D'Araújo Pinto Zampieri; Maria Sueli da Silva Kataoka; Nelson Antonio Bailão Ribeiro; Ruy Gastaldoni Jaeger; Artur Luiz da Silva; Rommel Thiago Jucá Ramos; Sérgio de Melo Alves Júnior; João de Jesus Viana Pinheiro
Journal:  Cells       Date:  2020-01-08       Impact factor: 6.600

8.  Revisiting the metallothionein genes polymorphisms and the risk of oral squamous cell carcinoma in a Brazilian population.

Authors:  R-R Rosa; M-A Garcia; P-T Alves; E-M Sousa; L-S Pimentel; L-D Barbosa; A-M Loyola; L-R Goulart; P-C Faria; S-V Cardoso
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.